CNS biopharma is rapidly investing in digital technologies to revolutionize clinical identification and monitoring of complex neurological disorders through more objective, frequent, sensitive, and less invasive measures of movement, speech, and cognition.
This is your must-attend meeting tackling the development of digital measures to revolutionize clinical assessments across neurological drug development.
Uniting Digital Health Biopharma with CNS Clinical Drug Developers to:
- Address the Standardization & Regulatory Acceptance of Digital Tools & Data Analysis as Endpoints in Complex Neurological Indications
- Discover Novel Innovations for Objective, Sensitive, & Non-Invasive Neurological Measures
- Ensure Confidence & Scalability with Emerging Digital Technologies
To know more visit: https://ter.li/nx0m2f